Cingulate is a holding company. Co. is engaged in clinical stage biopharmaceutical focused on the development of products using its key Precision Timed Release drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Co.'s two proprietary stimulant medications: CTx-1301 (dexmethylphenidate) and CTx-1302, are being developed for the treatment of ADHD intended for all patient segments: children (ages six to 12), adolescents (ages 13 to 17), and adults (ages18 plus). The CING average annual return since 2021 is shown above.
The Average Annual Return on the CING average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CING average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CING average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|